At the gene level, data from The Cancer Genome Atlas (TCGA) indicate that in many cancer types, the frequency of USP22 somatic mutations is very low, and gene sequencing and mRNA expression data reveal that USP22 gene is more frequently deleted or under-expressed than amplified or overexpressed in those same cancer types for which IHC studies found USP22 to be overexpressed [17–19], indicating transcriptional and or post transcriptional regulation of USP22 expression may be crucial to the level of USP22 protein in cancer. The gene discussed is USP22; the disease is cancer.